ArticleGenes2022
High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma.
Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Identification of Ferroptosis-related Genes Associated with the Prognosis of Hepatocellular Carcinoma.Cell biochemistry and biophysics · 2026Article
- Article
- ncRNA-Mediated Upregulation of AURKA Promotes Hepatocellular Carcinoma Progression and Alters the Immune Microenvironment.Bioinformatics and biology insights · 2026Article
- Mendelian Randomization and Bioinformatics Analysis Reveal the Potential Protective Role of Metformin in Primary Liver Cancer.Food science & nutrition · 2025Article
- MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma.Oncology letters · 2024Article
- Investigating the causal association between obesity and risk of hepatocellular carcinoma and underlying mechanisms.Scientific reports · 2024Article
- miR-101-3p-mediated role of PDZK1 in hepatocellular carcinoma progression and the underlying PI3K/Akt signaling mechanism.Cell division · 2024Article
- miR-101-3p suppresses proliferation of orbital fibroblasts by targeting pentraxin-3 in thyroid eye disease.PeerJ · 2024Article
- LncRNA-MALAT1: A Key Participant in the Occurrence and Development of Cancer.Molecules (Basel, Switzerland) · 2023Review
- Article
- Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is the predominant form of liver cancer and is accompanied by a complex regulatory network. Increasing evidence suggests that an abnormal gene expression of
methodsThe Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data were used to perform differential expression analysis and prognostic analysis. We used the Encyclopedia of RNA Interactomes (ENCORI) database to predict candidate miRNAs and lncRNAs that may bind to
results
conclusionSNHG6 or MALAT1/hsa-miR-101-3p/
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.